Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

Ítems similars

• Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations
  per: Wasan, Kishor M., et al.
  Publicat: (2003)
• Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels
  per: Wasan, Kishor M., et al.
  Publicat: (1999)
• Suppression of Murine Endotoxin Response by E5531, a Novel Synthetic Lipid A Antagonist
  per: Kobayashi, Seiichi, et al.
  Publicat: (1998)
• Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers
  per: Rossignol, Daniel P., et al.
  Publicat: (2004)
• Amphotericin B Lipid Complex or Amphotericin B Multiple-Dose Administration to Rabbits with Elevated Plasma Cholesterol Levels: Pharmacokinetics in Plasma and Blood, Plasma Lipoprotein Levels, Distribution in Tissues, and Renal Toxicities
  per: Ramaswamy, Manisha, et al.
  Publicat: (2001)